Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Increased by Montecito Bank & Trust

Montecito Bank & Trust raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,252 shares of the biopharmaceutical company’s stock after buying an additional 138 shares during the quarter. Montecito Bank & Trust’s holdings in Regeneron Pharmaceuticals were worth $892,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in REGN. AE Wealth Management LLC lifted its stake in Regeneron Pharmaceuticals by 19.4% in the second quarter. AE Wealth Management LLC now owns 547 shares of the biopharmaceutical company’s stock valued at $575,000 after buying an additional 89 shares during the last quarter. Gabelli Funds LLC increased its holdings in shares of Regeneron Pharmaceuticals by 1.8% in the 2nd quarter. Gabelli Funds LLC now owns 1,893 shares of the biopharmaceutical company’s stock worth $1,990,000 after acquiring an additional 34 shares during the period. Public Sector Pension Investment Board lifted its position in Regeneron Pharmaceuticals by 77.7% in the 2nd quarter. Public Sector Pension Investment Board now owns 3,841 shares of the biopharmaceutical company’s stock valued at $4,037,000 after purchasing an additional 1,679 shares during the last quarter. Insigneo Advisory Services LLC boosted its stake in Regeneron Pharmaceuticals by 11.2% during the 2nd quarter. Insigneo Advisory Services LLC now owns 1,059 shares of the biopharmaceutical company’s stock valued at $1,134,000 after purchasing an additional 107 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $24,038,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on REGN shares. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target for the company. Oppenheimer cut their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada decreased their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Stock Up 2.1 %

Shares of Regeneron Pharmaceuticals stock opened at $694.64 on Friday. The stock has a 50-day simple moving average of $730.57 and a 200-day simple moving average of $942.10. Regeneron Pharmaceuticals, Inc. has a 52-week low of $666.25 and a 52-week high of $1,211.20. The firm has a market cap of $76.33 billion, a price-to-earnings ratio of 17.19, a P/E/G ratio of 1.59 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.